LFCR logo

Lifecore Biomedical Inc. (LFCR)

$6.42

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LFCR

Market cap

$243166002

EPS

-0.93

P/E ratio

--

Price to sales

2.76

Dividend yield

--

Beta

0.993292

Price on LFCR

Previous close

$6.42

Today's open

$6.41

Day's range

$6.40 - $6.42

52 week range

$3.63 - $8.98

Profile about LFCR

CEO

Paul Josephs

Employees

382

Headquarters

Chaska, MN

Exchange

Nasdaq Global Select

Shares outstanding

37905846

Issue type

Common Stock

LFCR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LFCR

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Lifecore Biomedical to Participate at Upcoming Industry Conferences

CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events.

news source

GlobeNewsWire • Oct 7, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Oct 5, 2026

news preview

Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lifecore Biomedical, Inc. (NasdaqGS: LFCR) to Webster Equity Partners. Under the terms of the proposed transaction, shareholders of Lifecore will receive $6.28 in cash for each share of Lifecore that they own. KSF is seeking to determine whether this consideration and the process that led to it.

news source

Business Wire • Sep 30, 2026

news preview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)

BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

news source

GlobeNewsWire • Sep 30, 2026

news preview

Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

news source

GlobeNewsWire • Oct 1, 2026

news preview

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)

NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

news source

PRNewsWire • Sep 29, 2026

news preview

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lifecore Biomedical, Inc. (LFCR)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lifecore Biomedical, Inc. ("Lifecore Biomedical" or the "Company") (NASDAQ: LFCR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value right (CVR) per share. The investigation concerns whether the Lifecore Biomedical Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

news source

Newsfile Corp • Sep 29, 2026

news preview

Lifecore Biomedical to be Acquired by Webster Equity Partners

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a  49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone Payments Transaction Expected to Support Lifecore's Growth Objectives CHASKA, Minn. and WALTHAM, Mass.

news source

GlobeNewsWire • Sep 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Lifecore Biomedical Inc.

Open an M1 investment account to buy and sell Lifecore Biomedical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LFCR on M1